OBJECTIVES: The objectives of this study were to determine the seroprevalence and risk factors for herpes simplex virus (HSV) types 1 and 2 in patients attending 2 Canadian sexually transmitted disease (STD) clinics. STUDY: Stored sera were tested for the presence of IgG class antibodies to HSV-1 and HSV-2 and results linked to that obtained from a risk behavior questionnaire. RESULTS: Overall prevalences for HSV-1 and -2 were 56% and 19%, respectively. HSV-1 and -2 seropositivity was associated with increasing age, female gender, nonwhite ethnicity, and a history of STD. HSV-2 seropositivity was also associated with a history of genital herpes, presence of genital sores, and coinfection with either human immunodeficiency virus (HIV) or hepatitis C (HCV). CONCLUSIONS: Herpes simplex infection is common in this high-risk Canadian population. Our finding that HCV seropositivity was a significant predictor for HSV-2 seropositivity emphasizes the overlap between pathogens that are primarily thought to be bloodborne pathogens and sexually transmitted infections and the need to target prevention in these areas concurrently.
OBJECTIVES: The objectives of this study were to determine the seroprevalence and risk factors for herpes simplex virus (HSV) types 1 and 2 in patients attending 2 Canadian sexually transmitted disease (STD) clinics. STUDY: Stored sera were tested for the presence of IgG class antibodies to HSV-1 and HSV-2 and results linked to that obtained from a risk behavior questionnaire. RESULTS: Overall prevalences for HSV-1 and -2 were 56% and 19%, respectively. HSV-1 and -2 seropositivity was associated with increasing age, female gender, nonwhite ethnicity, and a history of STD. HSV-2 seropositivity was also associated with a history of genital herpes, presence of genital sores, and coinfection with either human immunodeficiency virus (HIV) or hepatitis C (HCV). CONCLUSIONS: Herpes simplex infection is common in this high-risk Canadian population. Our finding that HCV seropositivity was a significant predictor for HSV-2 seropositivity emphasizes the overlap between pathogens that are primarily thought to be bloodborne pathogens and sexually transmitted infections and the need to target prevention in these areas concurrently.
Authors: Mark Gilbert; Xuan Li; Martin Petric; Mel Krajden; Judith L Isaac-Renton; Gina Ogilvie; Michael L Rekart Journal: Can J Public Health Date: 2011 May-Jun
Authors: Robert S Remis; Juan Liu; Mona R Loutfy; Wangari Tharao; Anuradha Rebbapragada; Sanja Huibner; Maya Kesler; Roberta Halpenny; Troy Grennan; Jason Brunetta; Graham Smith; Tatjana Reko; Rupert Kaul Journal: PLoS One Date: 2016-07-08 Impact factor: 3.240
Authors: Ujjaldeep Jaggi; Shaohui Wang; Kati Tormanen; Harry Matundan; Alexander V Ljubimov; Homayon Ghiasi Journal: Front Immunol Date: 2018-12-07 Impact factor: 7.561
Authors: Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso Journal: BMC Infect Dis Date: 2009-04-01 Impact factor: 3.090
Authors: Sariah J Allen; Kevin R Mott; Aziz A Chentoufi; Lbachir BenMohamed; Steven L Wechsler; Christie M Ballantyne; Homayon Ghiasi Journal: J Virol Date: 2011-07-20 Impact factor: 5.103